Chinook Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced participation in upcoming investor conferences. The company will present at the Credit Suisse 31st Annual Healthcare Conference on November 9 at 1:25 PM EST and hold a fireside chat at the Stifel Healthcare Conference 2022 on November 15 at 3:35 PM EST. Interested investors can access the audio webcasts and recordings on the company’s website for up to 90 days after the events. Chinook focuses on precision medicines for kidney diseases, highlighting its leading programs including atrasentan and BION-1301.

SEATTLE, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming investor conferences:

• Credit Suisse 31^st Annual Healthcare Conference – Presentation on Wednesday, November 9^th at 1:25 pm EST.
  
  
• Stifel Healthcare Conference 2022 – Fireside chat on Tuesday, November 15^th at 3:35 pm EST.
  

To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the Investors section of Chinook’s website. The archived audio webcasts will remain available for replay on Chinook’s website for 90 days.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

FAQ

When is Chinook Therapeutics' presentation at the Credit Suisse Healthcare Conference?

Chinook Therapeutics will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 1:25 PM EST.

What is the date and format of Chinook's participation in the Stifel Healthcare Conference?

Chinook will participate in a fireside chat at the Stifel Healthcare Conference on November 15, 2022, at 3:35 PM EST.

How can investors access the audio webcasts of Chinook's presentations?

Investors can access the audio webcasts and subsequent recordings of Chinook's presentations on the Investors section of the company's website for 90 days.

What are Chinook Therapeutics' key programs?

Chinook's key programs include atrasentan for IgA nephropathy and BION-1301, an anti-APRIL monoclonal antibody, currently in trials for kidney diseases.